A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study.
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2012
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SCANSMART
- Sponsors Merck KGaA
- 11 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2011 Planned end date changed from 1 Nov 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 13 Dec 2010 Actual initiation date (Sep 2011) added as reported by ClinicalTrials.gov.